VBI Vaccines Inc.

NASDAQ:VBIV  
0.60
+0.02 (+4.00%)
7:55:46 PM EDT: $0.60 0.00 (0.30%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)160.62M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.98 Million
Adjusted EPS-$0.07
See more estimates
10-Day MA$0.57
50-Day MA$0.51
200-Day MA$0.81
See more pivots

VBI Vaccines Inc. Stock, NASDAQ:VBIV

160 2nd Street, floor 3, Cambridge, Massachusetts 02142
United States of America
Phone: +1.617.830.3031
Number of Employees:

Description

VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, Sci-B-Vac and VBI-2601. It also develops an enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on April 9, 1965 and is headquartered in Cambridge, MA.